Advanced or metastatic, unresectable Chondrosarcoma
INBXInhibrx Inc.Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Ozekibart (INBRX-109) (DR5 agonist) in Advanced or metastatic, unresectable Chondrosarcoma. The expected timing is based on the latest available company guidance and may change.
05/14/26:- BLA submission in April 2026 was reiterated. Acceptance timing remains TBA. 06/15/26:- BLA accepted; PDUFA goal date set for April 14, 2027. 08/13/26:- BLA acceptance and April 14, 2027 PDUFA date were reiterated.
Verification
Confirm timing and program details against the company announcement or filing.